炎症与肾功能指标改善CKD患者动脉粥样硬化血管事件和死亡预测:CRIC研究
在2399例无心血管病史的CRIC研究CKD患者中,中位随访7.3年,IL-6、TNF-α、纤维蛋白原和血清白蛋白独立关联复合ASVD-死亡结局。将eGFR、白蛋白尿和炎症复合评分加入Pooled Cohort Equation可改善预测(AUC从0.68升至0.73,P=0.003)。
要点
- IL-6、TNF-α、纤维蛋白原升高及白蛋白降低独立关联ASVD事件和死亡。
- 炎症复合评分与复合结局风险呈等级增加。
- 在传统风险方程中加入eGFR、白蛋白尿和炎症评分可改善预测。
核心结论
- 炎症生物标志物和肾功能指标独立关联CKD患者新发ASVD事件和死亡。
- 在传统心血管风险估计中加入炎症标志物和肾功能指标可改善预测。
研究设计与样本
- 观察性队列研究,纳入2399例无心血管病史的CRIC研究参与者。
主要发现
- 中位随访7.3年,分别有86、61、48和323例参与者发生心肌梗死、外周动脉疾病、卒中或死亡。
- IL-6每增加1个十分位数(aHR 1.12,95%CI 1.08-1.16,P<0.001)、TNF-α(aHR 1.09,95%CI 1.05-1.13,P<0.001)、纤维蛋白原(aHR 1.07,95%CI 1.03-1.11,P<0.001)和血清白蛋白(aHR 0.96,95%CI 0.93-0.99,P<0.002)独立关联复合ASVD-死亡结局。
- 包含上述4种生物标志物的炎症复合评分与复合结局风险呈等级增加相关。
- 基于PCEP、肾功能和炎症复合评分得出的风险五分位间,ASVD-死亡发生率逐渐增加。
- 将eGFR、白蛋白尿和炎症复合评分加入PCEP,复合结局的ROC曲线下面积从0.68(95%CI 0.66-0.71)改善至0.73(95%CI 0.71-0.76)(P=0.003)。
临床怎么用
- 在CKD患者心血管风险评估中,可考虑联合炎症生物标志物和肾功能指标以提高预测。
局限性
- 未获取心血管死亡数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Traditional risk estimates for atherosclerotic vascular disease (ASVD) and death may not perform optimally in the setting of chronic kidney disease (CKD). We sought to determine whether the addition of measures of inflammation and kidney function to traditional estimation tools improves prediction of these events in a diverse cohort of patients with CKD. STUDY DESIGN: Observational cohort study. SETTING & PARTICIPANTS: 2,399 Chronic Renal Insufficiency Cohort (CRIC) Study participants without a history of cardiovascular disease at study entry. PREDICTORS: Baseline plasma levels of biomarkers of inflammation (interleukin 1β [IL-1β], IL-1 receptor antagonist, IL-6, tumor necrosis factor α [TNF-α], transforming growth factor β, high-sensitivity C-reactive protein, fibrinogen, and serum albumin), measures of kidney function (estimated glomerular filtration rate [eGFR] and albuminuria), and the Pooled Cohort Equation probability (PCEP) estimate. OUTCOMES: Composite of ASVD events (incident myocardial infarction, peripheral arterial disease, and stroke) and death. ANALYTICAL APPROACH: Cox proportional hazard models adjusted for PCEP estimates, albuminuria, and eGFR. RESULTS: During a median follow-up of 7.3 years, 86, 61, 48, and 323 participants experienced myocardial infarction, peripheral arterial disease, stroke, or death, respectively. The 1-decile greater levels of IL-6 (adjusted HR [aHR], 1.12; 95% CI, 1.08-1.16; P<0.001), TNF-α (aHR, 1.09; 95% CI, 1.05-1.13; P<0.001), fibrinogen (aHR, 1.07; 95% CI, 1.03-1.11; P<0.001), and serum albumin (aHR, 0.96; 95% CI, 0.93-0.99; P<0.002) were independently associated with the composite ASVD-death outcome. A composite inflammation score (CIS) incorporating these 4 biomarkers was associated with a graded increase in risk for the composite outcome. The incidence of ASVD-death increased across the quintiles of risk derived from PCEP, kidney function, and CIS. The addition of eGFR, albuminuria, and CIS to PCEP improved (P=0.003) the area under the receiver operating characteristic curve for the composite outcome from 0.68 (95% CI, 0.66-0.71) to 0.73 (95% CI, 0.71-0.76). LIMITATIONS: Data for cardiovascular death were not available. CONCLUSIONS: Biomarkers of inflammation and measures of kidney function are independently associated with incident ASVD events and death in patients with CKD. Traditional cardiovascular risk estimates could be improved by adding markers of inflammation and measures of kidney function.
引用
- Amdur RL, Feldman HI, Dominic EA, et al. Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients With CKD: Findings From the CRIC Study. Am J Kidney Dis. 2018. PMID: 30545708. doi:10.1053/j.ajkd.2018.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。